Reference
- Milne C, Kaintin K. Impact of the new US health care reform legislation on the pharmaceutical industry: who are the real winners? Clin. Pharmacol. Ther. 88(5), 589–592 (2011).
- DiMasi J, Hansen R, Grabowski H, Lasagna L. Cost of innovation in the pharmaceutical industry. J. Health Econ. 10(2), 107–142 (1991).
- DiMasi J, Hansen R, Grabowski H. The price of innovation: new estimates of drug development costs. J. Health Econ. 22(2), 151–185 (2003).
- DiMasi J, Grabowski H. The cost of biopharmaceutical R & D: is biotech different? Managerial Decision Econ. 28(4–5), 469–479 (2007).
- DiMasi J, Grabowski H, Vernon J. R & D costs and returns by therapeutic category. Drug Info. J. 38(3), 211–224 (2004).
- DiMasi J, Grabowski H. Economics of new onclology drug development. J. Clin. Oncol. 25(2), 206–216 (2007).
- Hansen R, Chien R. The pharmaceutical development process: estimates of development costs and times and the effect of proposed regulatory changes. In: Issues in Pharmaceutical Economics. Chien RA ( Ed.). Lexington Books, Idaho falls, USA 151–191 (1979).
- Paul S, Mytella D, Dunwiddie C et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9(3), 203–214 (2010).
- Adams C, Brantner V. Estimating the cost of new drug development: is it really $802 million? Health Aff. 25(2), 420–428 (2006).
- US Congress OTA. Pharmaceutical R&D: costs, risks and rewards. U.S. Government Printing Office, Washington DC, USA (1993).
- Wiggins S. The Cost of Developing a New Drug. Pharmaceutical Manufacturers Association, Washington, DC, USA. (1987)
- Vernon J, Golec J, DiMasi J. Drug development costs when financial risk is measured using the Fama-French three factor model. Health Econ. 19(8), 1002–1005 (2010).
- Light D, Andrus J, Warburton R. Estimated research and development costs of rotavirus vaccine. Vaccine 27(47), 6627–6633 (2009).
- Turner R. New drug development design, methodology, and analysis. In: Statistics in Practice. Barnet V ( Eds.). Wiley Interscience, New Jersy, USA (2007)
- Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddard GL. Cost analysis. In: Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, UK 55–101(2005).
- HTA. Guidelines for the Economic Evaluation of Health Technologies, (3rd Edition). Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada (2006).
- Jacobs P, Ohinmaa A, Brady B. Providing systematic guidance in pharmacoeconomic guidelines for analysing costs. Pharmacoeconomics 23(2), 143–153 (2005).
- Adams C , Brantner V. Spending on new drug development. Health Econ. 19(2), 14–130 (2010).
- DiMasi. Research and development costs for new drugs by therapeutic category: as study of the US pharmaceutical industry. Pharmacoeconomics 7(2), 152–169 (1995).
- Young B, Surrusco M. Rx R&D myths: the case against the drug industry's R&D “Scare Card”. Public Citizen’s Congress Watch, Washington DC, USA (2001).
- The global alliance for TB drug development. Economics of TB drug development. (2001).
- Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy 100(1), 4–17 (2011).
- DiMasi. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 297–307 (2001).
- Douglas G, Samant V. The vaccine industry. In: Vaccines. Plotkin S, Orenstein W, Offit P ( Eds.). Saunders PA, USA, 37–44 (2012).
- Davis M, Butchart A, Wheeler J, Coleman M, Singer D, Freed G. Failure-to-success ratios, transition probabilities and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline. Vaccine 29(51), 9414–9416 (2011).
- Bernt E, Denoncourt R, Warner A. Prevnar -- The seven valent pnuemococcal conjugate vaccine. In: U.S. Markets for Vaccines. American Enterprise Institute for Public Policy, 105–117 (2009)
- Light D, Warburton R. Demythologizing the high costs of pharmaceutical research. BioSocieties 6, 34–50 (2011).
- Kellner J. Update on the success of the pneumococcal conjugate vaccine. Pediatr. Child Health 16(4), 233–236 (2011).
- Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201(1), 32–41 (2010).
- Advisory Committee on Immunization Practices. Update on pediatric invasive pneumococcal disease and recommended use of conjugate pneumococcal vaccines.. Clin. Infect. Dis. 36, 1–30 (2010).
- Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele D. Changing epidemiology of invasive pneumococcal disease in Canada 1998 to 2007: update from the calgary area Streptococcus pneumoniae research (CASPER) study. Clin. Infect. Dis. 49(2), 205–212 (2009).
- Pronker E, Weenen T, Commandeur H, Claassen E, Osterhaus A. Risk in vaccine research and development quantified. PLoS ONE 8(3), 1–7 (2013).
- Donati C, Rappuoli R. Reverse vaccinology in the 21st century: improvements over the original design. Ann. N. Y. Acad. Sci. 1285, 115–132 (2013).
- Dormitzer P, Grandi G, Rappuoli R. Structural vaccinology starts to deliver. Nat. Rev. Microbiol. 10(12), 807–813 (2012).
- Seib K, Zhao X, Rappuoli R. Developing vaccines in the era of genomics: a decade of reverse vaccinology. Clin. Microbiol. Infect. 18( Suppl. 18), 109–116 (2012).
- Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33(4), 530–541 (2010).
Websites
- PhRMA private-public RD spending (2013). www.phrma.org/private-public-rd-spending
- OECD. The international experience with R&D tax incentives (2011). www.finance.senate.gov/imo/media/doc/OECD%20SFC%20Hearing%20testimony%209%2020%2011.pdf
- Foreign affairs and international trade canada. biopharmaceuticals canada's competitive advantage. (2012). www.international.gc.ca/investors-investisseurs/assets/pdfs/download/canada-biopharmaceuticals-sector-2012.pdf
- Waterworth B. Simplifying government and non-government funding assistance programs (2010). www.riccentre.ca/wp-content/uploads/2011/06/Bob-Presentation.pdf
- Vaccines Europe (2013). www.vaccineseurope.eu/about-vaccines/key-facts-on-vaccines/
- Analysis of research and development expenditures (2013). www.pmprb-cepmb.gc.ca/english/view.asp?x=1503&mid=1334
- WHO essential medicines and health products information portal: research and development. www.apps.who.int/medicinedocs/en/d/Js6160e/4.html
- OECD. R&D tax incentives: rationale, design, evaluation. www.oecwww.oecd.org/fr/sti/ind/46586882.pdf.exd.org/fr/sti/ind/46586882.pdf
- NIH Annual funding (2013). www.nih.gov/about/budget.htm
- Medical research council UK (2013). www.mrc.ac.uk/About/Factsfigures/index.htm
- Cutliffe N. Research and development: fostering vaccine innovation in Canada (2010). www.biotech.ca/uploads/vic/vaccines_3_2010.pdf